UPDATE: Shares in dual-listed cancer diagnostics company Pacific Edge have fallen close to 90% on news its Cxbladder tests will no longer be covered by US national health insurance provider Medicare.
The company went into a trading halt yesterday having closed at 49.5c a share last Friday, but
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
